Arcturus Therapeutics

Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and nucleic acid-based therapeutics.

Placeholder

Arcturus Therapeutics

  • CureVac LogoCureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA TherapeuticsREAD MORE
  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE
  • Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA MedicinesREAD MORE
  • Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation to Advance a Novel LUNAR-Formulated mRNA CFTR TherapeuticREAD MORE
  • Takeda Pharmaceuticals logoTakeda Pharmaceuticals entered into collaboration with Arcturus Therapeutics to develop RNA-based therapeutics for the treatment of NASH.READ MORE
LUNAR® lipid mediated delivery enables delivery of nucleic acid medicines.

News & Events

  • July 23, 2018

    Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

    • July 23 2018
    • 0
    read more
  • July 20, 2018

    Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

    • July 20 2018
    • 0
    read more
  • July 9, 2018

    Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

    • July 9 2018
    • 0
    read more
  • June 18, 2018

    Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference

    • June 19 2018
    • 0
    read more
  • May 31, 2018

    Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO

    • May 31 2018
    • 0
    read more
  • May 30, 2018

    Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

    • May 31 2018
    • 0
    read more
  • May 29, 2018

    Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne

    • May 31 2018
    • 0
    read more
  • January 5, 2018

    Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives

    • January 5 2018
    • 0
    read more
  • January 4, 2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    • January 4 2018
    • 0
    read more